PHILADELPHIA September 19, 2023 – In an updated rapid, living practice points, the 鶹ֱapp (ACP) summarizes the latest evidence on the use of pharmacologic and biologic treatments of COVID-19 in the outpatient setting, specifically addressing the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. , was published today in Annals of Internal Medicine.
As reports reveal a late-summer and fall rise of COVID-19 cases and the continued presence of dis- and misinformation about the transmission, vaccines, and treatments, it’s critical to identify evidence-based treatments for COVID-19 that continue to evolve with new data.
Treatments supported in the updated guidance include the consideration of molnupiravir or nirmatrelvir-ritonavir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within five days of the onset of symptoms and at a high risk for progressing to severe disease.
The practice points do not support the use of ivermectin or sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. In addition, there are 18 other treatments for which no eligible studies were identified for the Omicron variant. More research is needed about the effectiveness of treatments and if effectiveness varies by patient characteristics, immunity status, symptom duration, and disease severity of COVID-19 in the outpatient setting.
Risk stratification is an important step before deciding the best approach to manage COVID-19 in the outpatient setting. The practice points note that the decision to initiate treatment for COVID-19 in the outpatient setting should be personalized and based on clinical judgment. Best practice is to use an informed decision-making approach with patients regarding potential treatment benefits and harms; patient characteristics (such as risk factors, comorbid conditions, and disease severity); patient preferences, and social determinants of health. Clinicians should review all medications and potential drug interactions before initiating outpatient treatment for COVID-19.
ACP’s Population Health and Medical Science Committee will maintain these practice points, as living by monitoring and assessing the impact of new evidence and updating as needed.
“The living practice points continue to be valuable clinical resources for internal medicine physicians and the health care community in treating COVID-19 in outpatient settings,” said Omar T. Atiq, M.D., FACP, President, ACP. “As the evidence continues to emerge, updates to this guidance will help to serve patients and physicians and continue to counter misinformation through the publication of evidence-based treatments.”
***
About the 鶹ֱapp
The 鶹ֱapp is the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 161,000 internal medicine physicians, related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on , and .
Contact: Andrew Hachadorian, (215) 351-2514, ahachadorian@acponline.org